Zai Lab
ZLAB
166 hedge funds and large institutions have $1.8B invested in Zai Lab in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 61 reducing their positions, and 20 closing their positions.
27% more call options, than puts
Call options by funds: $8.51M | Put options by funds: $6.7M
0.31% less ownership
Funds ownership: 6.25% → 5.94% (-0.31%)
2% less repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 61
2% less funds holding
Funds holding: 170 → 166 (-4)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
13% less capital invested
Capital invested by funds: $2.07B → $1.8B (-$269M)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$16.3M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$13.6M |
| 3 |
Goldman Sachs
New York
|
+$13.3M |
| 4 |
Fidelity International
Hamilton,
Bermuda
|
+$8.75M |
| 5 |
EFM
E Fund Management
Guangzhou,
China
|
+$7.74M |
Top Sellers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$66.7M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$37.9M |
| 3 |
Viking Global Investors
Stamford,
Connecticut
|
-$20.2M |
| 4 |
ICP
Indus Capital Partners
New York
|
-$12.8M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.98M |
ZLAB Hedge Fund Activity: Q4 2022 in Review
166 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Zai Lab (ZLAB) for Q4 2022, worth a combined $1.8B — down 13% from $2.07B a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of ZLAB and 18 opened new positions — a net loss of 2 holders — while 61 trimmed existing stakes and 60 added.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $16.3M. The largest seller was Janus Henderson Group, cutting an estimated $66.7M.
- 166 institutional investors held Zai Lab (ZLAB) as of Q4 2022, down from 170 in Q3 2022.
- Funds reported $1.8B of Zai Lab stock for Q4 2022, down 13% quarter-over-quarter.
- 18 funds opened new Zai Lab positions in Q4 2022 and 20 closed out, a net change of -2 holders.
- The largest Zai Lab buyer in Q4 2022 was Paradigm Biocapital Advisors, an estimated $16.3M added.
- The largest Zai Lab seller in Q4 2022 was Janus Henderson Group, an estimated $66.7M sold.
Based on aggregated 13F filings for Q4 2022.